KCCQ total symptom score, clinical outcome measures, and adverse events associated with omecamtiv mecarbil for heart failure with reduced ejection fraction: a systematic review and meta-analysis of randomized controlled trials.
Ramzi IbrahimAbdulbaril OlagunjuKristina TerraniChelsea TakamatsuGeorge KhludenevPreethi WilliamPublished in: Clinical research in cardiology : official journal of the German Cardiac Society (2023)
OM is generally well tolerated. We identified a reduced risk of stroke with use of OM. However, there was no improvement in other clinical outcomes or quality of life. Study protocol was registered in PROSPERO international prospective register of systematic reviews (CRD42022348423).